Smallpox Drug Development May Get Boost From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency convenes workshop to discuss use of animal models to demonstrate efficacy.
You may also be interested in...
Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral
The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.
Smallpox Treatments: Are Monkeypox Or Mousepox Acceptable Substitutes For Studying The Virus?
Smallpox has been eradicated for more than 30 years, but FDA isn't sure whether sponsors studying treatments in animals in case terrorists deliberately infected people can use substitute pathogens under the “Animal Rule.” The Antiviral Drugs Advisory Committee will weigh in on the issue.
Animal Rule's Study Designs For Anthrax Vaccine Show Utility For Other Products
When an FDA advisory panel gave its enthusiastic backing to the strategy for anthrax vaccine research developed by the agency's Center for Biologics Evaluation and Research, it also provided an important precedent for future applications of the "animal rule," which allows sponsors to conduct animal trials when human clinical trials would be impractical or unethical.